SAN MATEO, Calif. – JAN 07, 2026 – BigHat Biosciences, a protein therapeutics company that combines state-of-the-art AI models with a high-speed automated wet lab, today announced a collaboration with Eli Lilly and Company (Lilly) focused on advancing machine learning enabled biologics discovery through Lilly TuneLab. This project expands BigHat’s relationship with Lilly, which includes a previously disclosed collaboration focused on the discovery and engineering of next-generation antibody therapeutics.
Peyton Greenside, CEO and Co-Founder of BigHat, recognizes, “Current AI/ML models for antibody developability have limited ability to generalize to new sequences, largely because they are trained on limited formats and datasets of inconsistent quality. As a result, they are primarily used for prioritization amongst hits, rather than to meaningfully improve developability or inform early, high-impact development decisions. Greater confidence in the future of early-stage candidates has the potential to unlock exciting new targets and modalities that might otherwise be deprioritized.”
Lilly launched the TuneLab platform to give biotechnology companies access to actionable AI-enabled drug discovery models, which require high-accuracy predictions across the full diversity of therapeutic antibody candidates, despite their diverse biophysical properties. To support TuneLab’s continued evolution, BigHat will leverage its best-in-class ML expertise and Milliner™ platform to rapidly generate diverse, high-quality datasets suitable for use in a generalizable antibody developability foundation model.
About BigHat Biosciences
BigHat Biosciences is an AI-drive platform and therapeutics company combining a closed-loop, high-throughput wet lab with machine learning to design complex protein therapeutics. This unified platform enables rigorous benchmarking of AI models and rapid experimental validation across biologic modalities, targets, and therapeutic areas—unlocking differentiated, next-generation antibody therapies for patients with serious unmet needs.
Headquartered outside San Francisco, BigHat is a Series B biotechnology company with a pipeline that includes a next-gen ADC for GI cancers entering the clinic in 2026 and an avidity-driven TCE for solid tumors with an IND in 2026, in addition to several partnered programs. BigHat has raised more than $140 million from leading investors, including Section 32, Andreessen Horowitz (a16z), and 8VC.
